Please assess the completion status of the following clinical trial:

Trial Title: Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Alzheimer's Subject Selection: subjects who have a clinical diagnosis of mild to moderate Alzheimer's disease will be recruited for this study. The following criteria will be met for inclusion of AD subjects in this study:~* The participant is 50 years or older.~* Written informed consent is obtained.~* Participants have a clinical diagnosis of Alzheimer's disease based on National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria.~* CDR score ≥0.5 and \<2.~* Modified Hachinski Ischemia Scale score of ≤ 4.~* For females, non-child bearing potential or negative urine and blood pregnancy test on day of 123-I MNI-388 or 123-I MNI-390 injection.~Exclusion Criteria:~Alzheimer's subjects will be excluded from participation for the following reasons:~* The subject has signs or symptoms of another neurodegenerative disease including Parkinson's disease, diffuse Lewy body dementia, or history of significant cerebrovascular disease.~* The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness~* The subject has any disorder that may interfere with drug absorption distribution, metabolism, or excretion (including gastrointestinal surgery).~* The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.~* Clinically significant MRI evidence of vascular disease or alternative neurologic disorder~* Pregnancy~Concomitant therapy: patients may remain on a stable dose of anticholinesterase medication during the study. Use of donepezil (Aricept®), rivastigmine (Exelon®), galantamine (Razadyne®), tacrine (Cognex®), and memantine (Namenda®) are permitted during the study. Doses of these compounds must be stable for 2 months prior to the study. At each visit after the screening visit, the investigator will ask the patient whether any medications including OTC medications, were taken since the previous visit.~Use of antipsychotics for agitation and benzodiazepines for insomnia or anxiety is permitted. However, the use of these agents is not permitted within the 8 hours prior to administration of cognitive testing.~Inclusion Criteria:~Healthy Control Subject Selection: Healthy control subjects who have no neurological disease will be recruited for this study. The following criteria will be met for inclusion of healthy control subjects in this study:~* The participant is 50 years or older.~* Written informed consent is obtained.~* Negative history of neurological or psychiatric illness based on evaluation by a research physician.~* CDR score 0.~* For females, non-child bearing potential or negative urine and blood pregnancy test on day of 123-I MNI-388 or 123-I MNI-390 injection.~Exclusion Criteria:~Healthy control subjects will be excluded from participation for the following reasons:~* The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness.~* The subject has any disorder that may interfere with drug absorption distribution, metabolism, or excretion (including gastrointestinal surgery).~* The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.~* The subject has participated in another clinical study within the previous 30 days.~* Pregnancy~* Clinically significant MRI evidence of vascular disease or neurologic disorder

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Access I123MNI388/I123MNI390 and brain imaging (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).